Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · Real-Time Price · USD
2.590
+0.020 (0.78%)
Apr 3, 2025, 10:12 AM EDT - Market open
0.78%
Market Cap 15.25M
Revenue (ttm) 15.03M
Net Income (ttm) -11.14M
Shares Out 5.89M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,871
Open 2.530
Previous Close 2.570
Day's Range 2.530 - 2.600
52-Week Range 1.910 - 6.280
Beta 7.28
Analysts Strong Buy
Price Target 6.30 (+143.24%)
Earnings Date Mar 31, 2025

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and s... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Dec 11, 2020
Employees 123
Stock Exchange NASDAQ
Ticker Symbol VVOS
Full Company Profile

Financial Performance

In 2024, Vivos Therapeutics's revenue was $15.03 million, an increase of 8.91% compared to the previous year's $13.80 million. Losses were -$11.14 million, -18.02% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price forecast is $6.3, which is an increase of 143.24% from the latest price.

Price Target
$6.3
(143.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman...

2 days ago - Seeking Alpha

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Ma...

2 days ago - GlobeNewsWire

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

6 days ago - GlobeNewsWire

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

3 months ago - GlobeNewsWire

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants ...

4 months ago - Seeking Alpha

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

5 months ago - GlobeNewsWire

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payer...

6 months ago - GlobeNewsWire

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

7 months ago - GlobeNewsWire

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairma...

8 months ago - Seeking Alpha

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives...

8 months ago - GlobeNewsWire

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

8 months ago - GlobeNewsWire

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagn...

10 months ago - GlobeNewsWire

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit

10 months ago - GlobeNewsWire

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executiv...

11 months ago - Seeking Alpha

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives

11 months ago - GlobeNewsWire

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development a...

11 months ago - GlobeNewsWire

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea ...

1 year ago - GlobeNewsWire

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea

1 year ago - GlobeNewsWire

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...

1 year ago - GlobeNewsWire

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos De...

1 year ago - GlobeNewsWire

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. ...

1 year ago - GlobeNewsWire

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA Vivos unites influential women l...

1 year ago - GlobeNewsWire

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.

1 year ago - Market Watch

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).

1 year ago - Reuters